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Abstract (200 words max) 
 
Purpose of review: Review the evidence linking use of HIV protease inhibitors with excess risk of 
cardiovascular disease (CVD) in HIV+ populations.  
 
Recent findings: For the two contemporary most frequently used protease inhibitors, darunavir and 
atazanavir (both pharmacologically boosted with ritonavir [/r]), darunavir/r has been shown to be 
associated with increased  CVD risk. The effect is cumulative with longer exposure increasing risk and an 
effect size comparable to what has been observed for previously developed protease inhibitors. Biological 
mechanisms may be overlapping and include perturbed lipid metabolism and accumulation of cholesterol 
derivatives within macrophages. Conversely, atazanavir/r has not been shown to be associated with CVD, 
possible due its ability to increase cardioprotective bilirubin levels.  
 
Summary: Evidence linking protease inhibitors to CVD is based on observational studies only, whereas 
possible plausible biological explanation are well established and derived from randomised trials and 
controlled experiments. Given the possible association with clinical disease, a conservative approach to 
apply the data in daily practise is proposed which is focused on individualisation of care based on 
underlying risk of CVD.  
 
 
Introduction 
 
Recent guidelines indicate that antiretroviral therapy (ART) should be offered to all HIV+ persons 
irrespective of the stage of the infection. The benefit to the individual in early stages of disease comprise  a 
reduced risk of opportunistic infections, invasive bacterial infections, tuberculosis, and cancer (1,2). 
Additionally, the risk of onward HIV transmission via sex, placental or infected needles is virtually nil in 
persons with suppressed HIV viraemia(3,4).  Due to marked viral diversity within the body soon after initial 
infection, the probability of genetic variants rendering the virus less susceptible for a given antiretroviral 
drug is high. This can be overcome with combining agents, ensuring a genetic barrier of at least three and 
preferable four active antiretrovirals (5).  
 
Protease inhibitors (PIs) provide a high genetic barrier and were among the first developed in the second 
wave of antiretroviral drug discovery in 1994-1997. Of the first generation PIs, indinavir and saquinavir 
were the two most frequently used. Pill burden in HIV+ persons was reduced and pharmacokinetics 
significantly improved  by blocking the P450 enzyme system with ritonavir (/r)(6,7). Lopinavir/r was 
introduced six years later and was preferred because of better tolerability (7,8). Atazanavir/r and 
darunavir/r were subsequently introduced and remain the favoured PIs as part of a contemporary ART 
regimen (9,10). Atazanavir/r may lead to unharmful but cosmetically unacceptable icterus in a few 
individuals. Darunavir/r  causes gastrointestinal symptoms, but more rarely than seen in those treated with 
lopinavir/r (11,12).  
 
 
 
 
 
  
ART and CVD 
It remains uncertain whether ART reduces the risk of CVD. Data from the randomised controlled trial 
SMART (13), assessing continued versus intermittent use of ART, suggested that the risk may be lower for 
those using ART continuously, although this effect was of borderline significance (p=0.05)(14). Conversely, 
cohort studies performed among persons using the first generation ARVs as part of ART suggested a 
cumulative effect, with risk increasing linearly as  duration of ART increased (figure 1 (15, 16)). Of note, in 
the first paper describing this finding in observational data, (figure 1), the risk of CVD in those not yet 
having started ART was the lowest, indicating that most of the CVD events seen in HIV+ populations were 
associated with use of ART and not untreated HIV. Subsequent research until 2007-2010 indicated that this 
adverse effect was mainly associated with use of the PIs available at that time (16-19). Each of the PIs used 
were associated with a  gradually increasing CVD risk, so that the risk was not simply confined to those ever 
exposed, but increased as exposure increased, leading to  around a 50% increase in CVD incidence after five 
years of exposure.  
 
The range of the relative increased risk over five year of exposure in these studies was between 50% and 
100%.  Of note, the observational cohorts from where the data were derived from have been progressively 
more extensively treated with anti-dyslipidemic drugs over calendar time. This may at least in part be 
reflective of a reaction to the early reporting of excessive CVD risk by the responsible clinicians. Regardless, 
and if assuming that part of the mechanism from using PI’s is how they adversely affect lipid metabolism 
(see section below), this more aggressive approach to managing dyslipidaemia may likely have 
counteracted some of the risk associated with using PI’s. In support of this, the association was more 
pronounced in the earliest of the studies (15) than in subsequent reporting (16.19). 
 
Population based studies comparing risk of CVD in HIV+ versus HIV- populations also suggest a persistent 
elevated risk of CVD associated with HIV status (20-24). It is intriguing that adjustment for traditional CVD 
risk factors such as hypertension, smoking, dyslipidaemia and diabetes does not remove the CVD 
association with HIV status, suggesting that a higher prevalence of such traditional risk factors in the HIV+ 
population does not explain this finding. Recently, Klein and colleagues (24) published data suggesting 
some attenuation of the excess CVD risk over calendar time. This attenuation was potentially related to 
switches in approach to treat HIV using more CVD friendly  drugs and being progressively more aggressive 
in treating traditional CVD risk factors over time. 
 
It is possible that the excess risk of CVD from using ART may have underestimated the beneficial effects  of 
ART on the risk of CVD in the SMART study (14) referred to above. SMART was conducted during the era 
when antiretrovirals associated with an increased CVD risk were more widely used, and had that not been 
the case,  it is plausible that that the group randomised to continued use of ART may have had even lower 
rates of CVD. Importantly, given the design of the SMART trial and the  focus on persons that had been on 
ART for several years, there was a sizable group of relatively older persons in the trial which were at higher 
risk of CVD. In the randomised START trial, performed between 2010 and 2015 (2), there were no signs that 
timing of initiation of ART (immediately versus deferred) affected arterial elasticity (a proxy for 
atherosclerosis)(25). The number of CVD events was however too few to assess the impact of ART or type 
of ART directly. The trial focused on contemporary persons initiating ART, individuals were relatively young 
in CVD terms, and the primary objective was to assess whether all persons should be offered access to ART 
irrespective of the stage of their infection. There was strong evidence that offering ART to all was of clinical 
benefit. Given these results, the question of whether ART benefits persons in terms of their CVD risk or not 
has become less important. Conversely, the central question in relation to HIV care moving forward, and 
since the HIV population is aging and HIV is becoming a chronic disease associated with morbidity, is 
whether contemporarily used PIs accelerate CVD or not.  
 
Analysis of pooled data from 19 Janssen-sponsored clinical trials did not indicate an increased risk of CVD 
events with darunavir/r use over treatment durations of up to six years, but the study was limited to 5721 
persons followed for a median duration of approximately two years (26).  In contrast, Ryom et al. (27) 
recently presented data from one large observational study which for the first time indicated that 
darunavir/r was associated with a gradually increasing risk of CVD over five years of exposure similar to the 
earlier developed PIs. In contrast, atazanavir/r was not associated with CVD. This finding suggests, for the 
first time, that PIs as a class is not associated with excess risk of CVD. The key questions derived from this 
study is whether darunavir/r indeed has a CVD risk profile comparable to that seen for first and second 
generation PIs and furthermore, why atazanavir/r is not associated with what otherwise appears to be class 
effect on CVD risk?   
 
To address this, it is important to critically evaluate the evidence that support a causal link between use of 
PIs and increased risk of CVD.  
 
 
Quality of evidence linking PIs to CVD 
 
No adequately powered randomised trial has yet been conducted to assess the causative relationship 
between contemporary PIs and CVD.  Pivotal trials in HIV drug discovery are all powered to assess viral 
efficacy, and the sample size to establish this is sizably lower than required for studying clinical endpoints. 
The SMART (13) and START (2) trials, addressing strategic questions for whether to use ART continuously or 
not or to initiate ART in early HIV stages or not, were also not designed to directly address this.  
 
As such, it is data derived from careful analysis of adequately powered cohort studies, with their intrinsic 
limitations to establish causation, that are required to provide evidence to support the causal link. Clearly 
there are many limitations and bias associated with cohort studies, including most notably when assessing 
associations with antiretrovirals, the potential for confounding by indication. This arises when the decision 
to treat a specific individual with a given cART regimen is associated with the outcome.  For example, a 
person at perceived high risk of CVD, according to their physician, would be treated with a different ART 
regimen to one not thought to be at high risk of CVD.  Even with a wide range of information on potential 
confounding variables to adjust for, this bias may still play a role. None the less, attributes from these 
cohort study results with the specificity to darunavir/r, but not atazanavir/r and the biological gradient 
render it plausible that the detected association maybe causal. No study to date has been adequately 
powered to investigate if the observed association between darunavir/r and CVD declines when individuals 
are switched off darunavir/r, but if this proves to be the case it will be an important additional evidence to 
support causality of the association. 
 
The association between PIs and CVD is reproducible and seen consistently in a number of cohorts and 
when assessing different scenarios (15-19). This to some extent reduces – albeit does not remove – the risk 
that unknown or unmeasured confounders that could not be adjusted for might explain the association. 
Further, the association is characterised as a gradual increase, suggesting a dose-response effect and a 
slowly increasing risk as cumulative exposure increases (figure 1); a similar shape of the association was 
also seen for the darunavir/r signal (27). If causal, this  implies that PIs gradually worsen the underlying 
arterial pathology. There are at least two plausible mechanisms by which this may occur.  
 
PIs perturbs lipid metabolism and leads to a pro-atherogenic state. This effect is demonstrated in multiple 
randomised controlled trials (6-12). Table 1 shows data from a recent publication from the START trial by 
Baker et al (28); of note, total and LDL cholesterol levels during follow-up were increased for those starting 
PI’s immediately versus deferred. Molina et al. also demonstrated this effect in relation to darunavir/r 
when compared to a drug (dolutegravir) from the integrase inhibitor drug class which are known not to 
affect lipid metabolism.  (11). Of note, adjustment for cholesterol levels after starting PIs in observational 
studies attenuates (but does not remove) the association between PI exposure and CVD risk (17, 19). This 
attenuation of the association however was not seen for the  darunavir/r signal (27). This body of evidence 
would  suggest that although PIs perturb lipid metabolism, and that this perturbation may partly be 
responsible for the association between excess risk of CVD for some PI’s, the potential for lipid perturbation 
may not be the same for all PIs and therefore is not a  consistent plausible biological explanation  The other 
plausible explanation was observed in 2003 (29). PIs upregulate the accumulation of cholesteryl esters in 
macrophages via induction of CD36; an effect that oestrogen attenuates (30). Macrophages of course are 
central in the formation of atherosclerotic plaques. PIs might further inhibit apoptosis, which could 
potentially alter the turnover of plaque macrophages.  While the role of plaque apoptosis is debated and 
enhanced apoptosis in certain cells might alter plaque stability, inhibition may also lead to retention of 
harmful macrophage phenotypes (31). 
 
Atazanavir/r share the two mechanisms outlined above with darunavir/r, yet the D:A:D study could not find 
any evidence of an increased risk of CVD associated with atazanavir/r (27). It was been proposed that the 
elevation of bilirubin caused by atazanavir/r may reduce any association between atazanavir/r and 
increased CVD risk (32-34). Marconi and colleagues reported that higher bilirubin levels were associated 
with lower risk of CVD independent of other confounders (35).  
 
It is questionable whether any sufficiently powered randomised clinical trial will ever be conducted to 
confirm the causal relationship between darunavir/r and other PIs and excess risk of CVD. This continued 
uncertainty needs to be incorporated into clinical management of HIV+ persons and considered alongside 
the other risks and benefits associated with ART. It would seem reasonable to approach the association 
between darunavir/r and CVD risk  conservatively, taking into account both relative versus absolute risk as 
well as benefits and risks of ART.   
 
Relative versus absolute risk 
 
The key study findings reporting an association between PIs and  CVD expresses their result in relative 
terms. That is, the risk of CVD was increased by e.g. 50%-100% after five years of use. However, if the 
person’s underlying risk of CVD is very low, a 50%-100% increase in risk is minimal and the person will 
remain at a low risk of CVD whether or not they are exposed to PIs.  The opposite is  true if the underlying 
risk is high. There are now reliable and validated risk algorithms able to estimate the underlying risk (34). 
These risk algorithms are critical to use as part of daily practise to be able to individualise care. Not only are 
they able to differentiate risk of contracting adverse drug reactions, such as CVD, but they also focus 
attention to the factors in the algorithms that influence the underlying risk including those being potentially 
modifiable including other types of antiretroviral drugs (36).   
 
Balancing benefits and harm 
 
The overall philosophy of practising medicine is to provide care for the individual to optimise the chance of 
benefit by weighing and potentially reducing  risk for causing harm. Quantification of risk and  harm, as 
outlined in the section above, is hence critically important to perform. Also, the benefits from using ART (as 
opposed to not doing so) weigh very heavily in favour of using ART; the introduction of combination ART 
has led to a 90% reduction in morbidity and mortality associated with HIV (37). For PIs, given the high 
genetic barrier for drugs in this class (in particular darunavir/r), these drugs are an important component of 
the  accessible antiretroviral drugs in situations where patients have already acquired drug resistance or in 
situations where the risk of variable adherence (and hence acquisition of drug resistance) is high.  
 
Conclusions 
 
PIs remains an integral part of ART, in particular due to their ability to maintain full control of viral 
replication in persons harbouring HIV resistant to several other of the available antiretroviral drugs. A small 
increased risk of CVD, which increases with increased length of exposure, may be an adverse effect from 
using most drugs from within this drug class, other than atazanavir/r. The evidence basis for this association 
is based largely on analyses from observational studies with their inherited limitations and inability to 
establish causality. It is plausible that the effect is driven by perturbation of cholesterol metabolism. 
Additional research, including adequately powered randomised trials, is required to further substantiate 
the evidence base for using this important drug class used as part of ART.  
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Table 1. Lipid differences in the START study comparing persons starting immediate versus deferred on 
drugs from one drug (efavirnez) and drugs from protease inhibitors and integrase inhibitor drug classes 
(28).  
  Pre-specified ART 
  
EFV (n=3,516) PI (n=815) INSTI (n=183) 
Measure 
I-D a 
Mean Diff. [95% CI] 
I-D a 
Mean Diff. [95% CI] 
I-D a 
Mean Diff. [95%CI] 
Total-C (mg/dL) 13.2 [11.5, 14.9]* 8.7 [5.2, 12.1]* -2.4 [-10.1, 5.3] 
LDL-C (mg/dL) 6.5 [5.0, 7.9]* 3.7 [0.7, 6.7] -1.1 [-7.8, 5.7] 
HDL-C (mg/dL) 5.8 [5.2, 6.4]* 2.2 [0.9, 3.5]* 0.4 [-2.5, 3.4] 
Total-C:HDL-C -0.2 [-0.2, -0.1]** -0.0 [-0.2, 0.1] -0.2 [-0.5, 0.2] 
BMI (kg/m2) -0.3 [-0.4, -0.2]** -0.1 [-0.2, 0.1] -0.0 [-0.4, 0.4] 
 
  
Figure 1. Myocardial infarction by exposure to antiretroviral therapy* used between 2000-2002 (15).  
 
 
*: Most antiretroviral therapy used at the time included one of the first generation protease inhibitors. 
Note, the gradually increasing with longer use (27% increased per year of use).   
